PHP
CSTL icon

Parkman Healthcare Partners’s Castle Biosciences CSTL Stock Holding History

Parkman Healthcare Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Sell
126,150
-24,408
-16% -$799K 0.32% 75
2025
Q4 		$5.86M Sell
150,558
-325,010
-68% -$10.5M 0.56% 56
2025
Q3 		$10.8M Buy
475,568
+123,306
+35% +$2.5M 1.13% 32
2025
Q2 		$7.19M Buy
352,262
+1,711
+0.5% +$31.7K 0.83% 48
2025
Q1 		$7.02M Buy
350,551
+45,922
+15% +$1.14M 0.83% 43
2024
Q4 		$8.12M Buy
304,629
+8,558
+3% +$261K 1.08% 33
2024
Q3 		$8.44M Buy
296,071
+18,176
+7% +$463K 1.08% 34
2024
Q2 		$6.05M Sell
277,895
-89,513
-24% -$1.99M 0.81% 44
2024
Q1 		$8.14M Buy
367,408
+10,252
+3% +$223K 1% 36
2023
Q4 		$7.71M Buy
357,156
+132,564
+59% +$2.33M 1.09% 31
2023
Q3 		$3.79M Buy
224,592
+76,590
+52% +$1.34M 0.7% 41
2023
Q2 		$2.03M Buy
+148,002
New +$3M 0.35% 75
2021
Q1 		– Sell
-22,831
Closed -$1.53M – 88
2020
Q4 		$1.53M Sell
22,831
-7,172
-24% -$389K 0.39% 65
2020
Q3 		$1.54M Buy
30,003
+5,003
+20% +$223K 0.41% 65
2020
Q2 		$942K Buy
+25,000
New +$854K 0.27% 71

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkman Healthcare Partners's CSTL Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its Castle Biosciences (CSTL) stake by 16% in Q1 2026, selling an estimated $799K and leaving 126,150 shares worth $3.1M. The position accounts for 0.32% of the portfolio, ranked #75.

Parkman Healthcare Partners first reported a position in CSTL in Q2 2020 and has held it in 15 quarters since. The position peaked at $10.8M in Q3 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Parkman Healthcare Partners held 126,150 shares of Castle Biosciences worth $3.1M as of Q1 2026.
  • Parkman Healthcare Partners sold 24,408 Castle Biosciences shares in Q1 2026, an estimated $799K.
  • Castle Biosciences made up 0.32% of Parkman Healthcare Partners's portfolio in Q1 2026, its #75 holding.
  • Parkman Healthcare Partners first reported a position in Castle Biosciences in Q2 2020 and has held it in 15 quarters since.
  • Parkman Healthcare Partners's Castle Biosciences position peaked at $10.8M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.